Medical News

RSS

Alzheimer's disease: Gene expression level influences promotion of disorder or protection against development

Using sophisticated techniques that scan the genomes of patients, researchers at the Mayo Clinic campus in Florida have found that a gene appears to either help protect against development of Alzheimer's disease, or promote the disorder depending on the level of gene in the brain.

18 Mar 2010

Enzo Biochem announces supply and distribution agreement between Enzo Life Sciences and Cancer Genetics

Enzo Biochem, Inc., a vertically integrated biotechnology company engaged in the research, development, manufacture, licensing and marketing of innovative health care products, platforms and services based on molecular and cellular technologies, announced today a supply and distribution agreement between Enzo Life Sciences and privately-owned Cancer Genetics Inc., a leading producer of nucleic acid products used in genomic research.

18 Mar 2010

Idaho Health Freedom Act does nothing to tackle state's health care crisis, says AARP

The health care crisis hundreds of thousands of Idahoans face every day may have just gone from bad to worse with the stroke of a pen. Today, Governor C.L. "Butch" Otter signed the Idaho Health Freedom Act into law, a bill strongly opposed by AARP.

18 Mar 2010

Taking dietary supplements for adrenal fatigue may do more harm than good

Taking vitamins or supplements to treat "adrenal fatigue" may do more harm than good, says Todd Nippoldt, M.D., a Mayo Clinic expert in hormone disorders affecting the adrenal glands.

18 Mar 2010

Esteem hearing system receives FDA approval for treatment of sensorineural hearing loss

The U.S. Food and Drug Administration today announced the approval of the Esteem – an implanted hearing system used to treat moderate to severe sensorineural hearing loss, a type of permanent hearing loss.

18 Mar 2010

Agendia to participate in groundbreaking clinical trial for breast cancer

Agendia, a world leader in molecular cancer diagnostics, announced today it will participate in the highly anticipated I-SPY 2 TRIAL for breast cancer, set to launch at the first of nearly twenty research sites.

18 Mar 2010

Democrats take aim at deficit targets, continue to wait for CBO numbers on health overhaul

"With Congress just days away from an expected vote, Democrats still hadn't settled on final language of the bill and until they do the Congressional Budget Office can't release an estimate for how much the complete package would cost." House Majority Leader Steny Hoyer (D., Md.) said yesterday that "he hoped Democratic leaders would be able to lock down final details soon.

18 Mar 2010

New findings promise to have fundamental significance in the fight against cancer

Cells have two different protection programs to safeguard them from getting out of control under stress and from dividing without stopping and developing cancer. Until now, researchers assumed that these protective systems were prompted separately from each other.

18 Mar 2010

Dems newly-favored tactic to advance health measure draws GOP rage

The latest strategy House Democratic leaders have considered for passing the health overhaul bill would allow lawmakers to approve a Senate-passed version of the bill without a direct vote, The Washington Post reports. Instead, a so-called "self-executing rule would say that the Senate's version of health-care legislation would be deemed approved if House members adopt a set of changes to that bill."

18 Mar 2010

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers

The Biomarkers Consortium, a unique public-private partnership that includes the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), and major pharmaceutical companies, led by the Foundation for the National Institutes of Health (FNIH), today announced the launch of a highly anticipated clinical trial to help screen promising new drugs being developed for women with high risk, fast-growing breast cancers—women for whom an improvement over standard treatment could dramatically change the odds of survival.

18 Mar 2010

Phase 2a clinical trial results of CPEX Pharmaceuticals' Nasulin insulin

CPEX Pharmaceuticals Inc. today reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Company’s nasal insulin product, Nasulin™. The study was designed to evaluate the efficacy and safety of Nasulin versus placebo over a 6-week treatment period in subjects with Type 2 diabetes who were being treated with basal insulin and oral anti-diabetes agents.

18 Mar 2010

Aetna, SBUH announce new agreement for hospital’s participation in Aetna network

Aetna and Stony Brook University Hospital are pleased to announce today a new agreement for the hospital’s participation in the Aetna network. The agreement is effective through April 30, 2011, and will enable Stony Brook physicians currently participating with Aetna to continue their participation uninterrupted.

18 Mar 2010

Cangene receives European Commission approval to market ImmunoGam

Cangene Corporation today reports that it has received European Commission approval to market Cangene's ImmunoGam(TM) (Human Hepatitis B Immunoglobulin), indicated for immunoprophylaxis of hepatitis B.

18 Mar 2010

As Medicare pay shrinks, some California doctors hike patient fees

Kaiser Health News staff writer Christopher Weaver writes about a California cardiology group that has confronted steep Medicare cuts with a tactic that may irk patients who already face soaring health costs.

18 Mar 2010

CytoDyn commences full humanization of Cytolin immune therapy for treating HIV/AIDS

CytoDyn, Inc. has begun full humanization of Cytolin®, the Company’s unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.

17 Mar 2010

Obama to appear on Fox News; Heath reform will be high on his topic list

New York Times: President Obama is scheduled to give an interview with Bret Baier of Fox News Wednesday evening. The interview comes "at the height of a week in which Democrats, including Mr. Obama, are pressing allies and lawmakers to push ahead to get the health care bill passed in the House despite solid Republican opposition and the lessening of public support for the legislation." The interview comes after Obama administration aides last year criticized Fox News for its political coverage and commentary (3/16).

17 Mar 2010

Nabi Biopharmaceuticals commences second Phase III study of NicVAX for treating nicotine addiction

Nabi Biopharmaceuticals announced that it has initiated the second of two pivotal Phase III clinical trials for NicVAX® (Nicotine Conjugate Vaccine), the company's innovative and proprietary vaccine to treat nicotine addiction and prevent smoking relapse. The FDA has agreed with Nabi on the study design, protocol and end points through a Special Protocol Assessment (SPA). The SPA forms a basic foundation to support approval of a New Drug Application. The Company also received scientific advice from the European Medicines Agency (EMEA) that confirms and supports the trial protocol.

17 Mar 2010

Cut looms for Medicare payments to doctors

Marketwatch/The Seattle Times reports on the looming 21 percent cut to physicians' Medicare payments. "The cut was to take effect March 1 until Congress delayed it by 30 days. The Senate then voted last Wednesday to postpone the cut an additional six months as part of a larger bill that extends unemployment benefits. The measure now moves to the House."

17 Mar 2010

Access MediQuip enhances Recall Management Service for implantable devices

Access MediQuip, LLC, the nation's first and largest provider of outsourced implantable medical device management solutions to the healthcare industry, announced today it has enhanced its proprietary Recall Management Service, "RMS," for its customers nationwide. The new release is designed to protect patients, inform and empower surgeons and facilities, and help payers improve quality while managing cost.

17 Mar 2010

AstraZeneca's CRESTOR: Health Canada approves new indication

AstraZeneca announced today that Health Canada has approved CRESTOR (rosuvastatin calcium) to reduce the risk of nonfatal myocardial infarction (heart attack), nonfatal stroke, and coronary artery revascularization in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease.

17 Mar 2010

Medical News

Alzheimer's disease: Gene expression level influences promotion of disorder or protection against development

Enzo Biochem announces supply and distribution agreement between Enzo Life Sciences and Cancer Genetics

Idaho Health Freedom Act does nothing to tackle state's health care crisis, says AARP

Taking dietary supplements for adrenal fatigue may do more harm than good

Esteem hearing system receives FDA approval for treatment of sensorineural hearing loss

Agendia to participate in groundbreaking clinical trial for breast cancer

Democrats take aim at deficit targets, continue to wait for CBO numbers on health overhaul

New findings promise to have fundamental significance in the fight against cancer

Dems newly-favored tactic to advance health measure draws GOP rage

I-SPY 2: The Biomarkers Consortium launches clinical trial for high risk, fast-growing breast cancers

Phase 2a clinical trial results of CPEX Pharmaceuticals' Nasulin insulin

Aetna, SBUH announce new agreement for hospital’s participation in Aetna network

Cangene receives European Commission approval to market ImmunoGam

As Medicare pay shrinks, some California doctors hike patient fees

CytoDyn commences full humanization of Cytolin immune therapy for treating HIV/AIDS

Obama to appear on Fox News; Heath reform will be high on his topic list

Nabi Biopharmaceuticals commences second Phase III study of NicVAX for treating nicotine addiction

Cut looms for Medicare payments to doctors

Access MediQuip enhances Recall Management Service for implantable devices

AstraZeneca's CRESTOR: Health Canada approves new indication

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News